Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma

Sean O’Quinn, Xiao Xu, Ian Hirsch AstraZeneca, Gaithersburg, MD, USA Background: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha–directed cyt...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	O'Quinn S, Xu X, Hirsch I
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Dove Medical Press 2019-01-01
Σειρά:	Journal of Asthma and Allergy
Θέματα:	asthma benralizumab eosinophils interleukin-5 receptor monoclonal antibody patient-reported outcomes
Διαθέσιμο Online:	https://www.dovepress.com/daily-patient-reported-health-status-assessment-improvements-with-benr-peer-reviewed-article-JAA
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!